These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18214474)

  • 1. TGF beta secreted by B16 melanoma antagonizes cancer gene immunotherapy bystander effect.
    Penafuerte C; Galipeau J
    Cancer Immunol Immunother; 2008 Aug; 57(8):1197-206. PubMed ID: 18214474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization with interleukin-2/interferon-gamma double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma.
    Kim TS; Xu WS; Sun T; Cohen EP
    Melanoma Res; 1995 Aug; 5(4):217-27. PubMed ID: 7496156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
    Stagg J; Wu JH; Bouganim N; Galipeau J
    Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ex vivo and in vivo adenovirus-mediated gene therapy strategies induce a systemic anti-tumor immune defence in the B16 melanoma model.
    Bonnekoh B; Greenhalgh DA; Chen SH; Block A; Rich SS; Krieg T; Woo SL; Roop DR
    J Invest Dermatol; 1998 Jun; 110(6):867-71. PubMed ID: 9620291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.
    Asada H; Kishida T; Hirai H; Satoh E; Ohashi S; Takeuchi M; Kubo T; Kita M; Iwakura Y; Imanishi J; Mazda O
    Mol Ther; 2002 May; 5(5 Pt 1):609-16. PubMed ID: 11991752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
    Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
    Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.
    Sampson JH; Archer GE; Ashley DM; Fuchs HE; Hale LP; Dranoff G; Bigner DD
    Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10399-404. PubMed ID: 8816812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
    van Elsas A; Hurwitz AA; Allison JP
    J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
    Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
    Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity.
    Hong B; Li H; Lu Y; Zhang M; Zheng Y; Qian J; Yi Q
    Mol Cancer; 2014 May; 13():132. PubMed ID: 24884733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination using melanoma cells treated with p19arf and interferon beta gene transfer in a mouse model: a novel combination for cancer immunotherapy.
    Medrano RF; Catani JP; Ribeiro AH; Tomaz SL; Merkel CA; Costanzi-Strauss E; Strauss BE
    Cancer Immunol Immunother; 2016 Apr; 65(4):371-82. PubMed ID: 26887933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor.
    Arca MJ; Krauss JC; Aruga A; Cameron MJ; Shu S; Chang AE
    Cancer Gene Ther; 1996; 3(1):39-47. PubMed ID: 8785710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.
    Lemay CG; Rintoul JL; Kus A; Paterson JM; Garcia V; Falls TJ; Ferreira L; Bridle BW; Conrad DP; Tang VA; Diallo JS; Arulanandam R; Le Boeuf F; Garson K; Vanderhyden BC; Stojdl DF; Lichty BD; Atkins HL; Parato KA; Bell JC; Auer RC
    Mol Ther; 2012 Sep; 20(9):1791-9. PubMed ID: 22760544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection.
    Hara I; Nguyen H; Takechi Y; Gansbacher B; Chapman PB; Houghton AN
    Int J Cancer; 1995 Apr; 61(2):253-60. PubMed ID: 7705956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A family of bicistronic vectors to enhance both local and systemic antitumor effects of HSVtk or cytokine expression in a murine melanoma model.
    Castleden SA; Chong H; Garcia-Ribas I; Melcher AA; Hutchinson G; Roberts B; Hart IR; Vile RG
    Hum Gene Ther; 1997 Nov; 8(17):2087-102. PubMed ID: 9414257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
    Li B; Lin J; Vanroey M; Jure-Kunkel M; Jooss K
    Clin Immunol; 2007 Oct; 125(1):76-87. PubMed ID: 17706463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transforming growth factor-beta down-regulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis.
    Ma D; Niederkorn JY
    Immunology; 1995 Oct; 86(2):263-9. PubMed ID: 7490128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-type or cytokine gene-transduced melanoma.
    Lipshy KA; Kostuchenko PJ; Hamad GG; Bland CE; Barrett SK; Bear HD
    Ann Surg Oncol; 1997 Jun; 4(4):334-41. PubMed ID: 9181234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.